Form 4: Septerna CFO Granted 125,000 Stock Options

Septerna Inc.'s Chief Financial Officer, Gil M. Labrucherie, was granted 125,000 stock options with an exercise price of $25.41.

Summary

• Gil M. Labrucherie, Chief Financial Officer of Septerna, Inc., was granted 125,000 stock options.
• The stock options have an exercise price of $25.41 per share.
• The transaction date for this grant was February 6, 2026.
• Vesting for the options begins on March 1, 2026, with 2/48th of the shares, and the remaining shares vest in 46 substantially equal monthly installments thereafter, subject to continuous service.
• The expiration date for these stock options is February 5, 2036.
• Following this transaction, Gil M. Labrucherie beneficially owns 125,000 derivative securities directly.
• Mark A. Wilson was appointed as a substitute attorney-in-fact for Gil M. Labrucherie to execute SEC filings, effective February 10, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction, slightly positive as it aligns the CFO's interests with shareholders through equity incentives, without indicating any immediate operational or financial changes.

Positives

• The grant of 125,000 stock options to the Chief Financial Officer aligns management's long-term interests with those of shareholders.
• The vesting schedule, tied to continuous service, incentivizes the CFO's continued commitment to the company's performance and value creation.

Negatives

• No direct negatives are apparent from this routine insider transaction filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• No direct quotes or paraphrased statements from company management are included in this Form 4 filing.

Industry Context

StockSavvy.ai notes that equity grants, such as stock options, are a common component of executive compensation packages across the biotechnology and pharmaceutical industries. These grants are designed to align the interests of key executives with those of shareholders by providing a direct financial incentive tied to the company's stock performance. The exercise price and vesting schedule are typical for such arrangements, reflecting a long-term retention and performance strategy.

Comparison to Industry Standards

• This option grant is a standard practice for executive compensation in growth-oriented sectors like biotechnology, comparable to grants seen at companies such as Moderna or BioNTech for their executive teams.
• The vesting schedule, typically over several years, is consistent with industry benchmarks aimed at retaining talent and incentivizing long-term value creation, similar to equity incentive plans at peer companies like Vertex Pharmaceuticals or Regeneron Pharmaceuticals.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are mentioned in this filing.

Related Party Transactions

• No related party transactions are disclosed in this filing beyond the standard executive compensation.

Stakeholder Impact

• Shareholders: The option grant aligns the CFO's financial incentives with shareholder value creation, potentially fostering long-term growth.
• Employees: The vesting schedule incentivizes the CFO's continued service, contributing to leadership stability.

Next Steps

• The granted stock options will begin vesting on March 1, 2026, and continue in monthly installments, subject to the CFO's continuous service.

Key Dates

Keywords

Septerna, SEPN, Stock Options, Insider Transaction, Form 4, CFO, Equity Grant, Executive Compensation